用于Sirna递送的纳米载体用于治疗黑色素瘤:系统综述。

IF 2.8 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug delivery Pub Date : 2023-04-25 DOI:10.2174/1567201820666230425234700

Brenda Regina de Araujo, Tatielle do Nascimento, Ana Paula Dos Santos Matos, Vanessa Brandão de Souza Belmiro, Mariana Sato de Souza de Bustamante Monteiro, Ralph Santos-Oliveira, Eduardo Ricci-Junior

{"title":"用于Sirna递送的纳米载体用于治疗黑色素瘤:系统综述。","authors":"Brenda Regina de Araujo, Tatielle do Nascimento, Ana Paula Dos Santos Matos, Vanessa Brandão de Souza Belmiro, Mariana Sato de Souza de Bustamante Monteiro, Ralph Santos-Oliveira, Eduardo Ricci-Junior","doi":"10.2174/1567201820666230425234700","DOIUrl":null,"url":null,"abstract":"Background: Melanoma is a malignant skin cancer type with a high lethality rate due to active metastasis. Among the risk factors for its development is exposure to ultraviolet radiation (UV) and phenotypical characteristics such as clear skin and eyes. Given the difficulties of the conventional therapy, the high cost of the treatment and the low bioavailability of drugs, it is important to develop new therapeutic methods to circumvent this situation. Nanosystems such as micelles, liposomes and nanoparticles present advantages when compared to conventional treatments.Objective: The objective of this paper is to carry out a literature review based on articles that dealt with the use of siRNA-loaded nanosystems for the treatment of melanoma, with trials carried out in vivo to assess tumor size.Methods: The search was conducted in the Web of Science and PubMed databases considering the last 5 years, that is, the period between January 2017 to December 2021. The \"SiRNA and Drug Delivery Systems and Melanoma\" keywords were used in both databases, and the articles were analyzed using the inclusion and exclusion criteria established for this paper.Results: The results obtained indicated that using siRNA transported via nanosystems was capable of silencing the BRAF tumor genes and of reducing tumor size and weight, not presenting in vitro and/or in vivo toxicity.Conclusion: Such being the case, the development of these systems becomes a non-invasive and promising option for the treatment of melanoma.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2023-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nanocarriers for Sirna Delivery Aimed at the Treatment of Melanoma: Systematic Review.\",\"authors\":\"Brenda Regina de Araujo, Tatielle do Nascimento, Ana Paula Dos Santos Matos, Vanessa Brandão de Souza Belmiro, Mariana Sato de Souza de Bustamante Monteiro, Ralph Santos-Oliveira, Eduardo Ricci-Junior\",\"doi\":\"10.2174/1567201820666230425234700\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Melanoma is a malignant skin cancer type with a high lethality rate due to active metastasis. Among the risk factors for its development is exposure to ultraviolet radiation (UV) and phenotypical characteristics such as clear skin and eyes. Given the difficulties of the conventional therapy, the high cost of the treatment and the low bioavailability of drugs, it is important to develop new therapeutic methods to circumvent this situation. Nanosystems such as micelles, liposomes and nanoparticles present advantages when compared to conventional treatments.Objective: The objective of this paper is to carry out a literature review based on articles that dealt with the use of siRNA-loaded nanosystems for the treatment of melanoma, with trials carried out in vivo to assess tumor size.Methods: The search was conducted in the Web of Science and PubMed databases considering the last 5 years, that is, the period between January 2017 to December 2021. The \\\"SiRNA and Drug Delivery Systems and Melanoma\\\" keywords were used in both databases, and the articles were analyzed using the inclusion and exclusion criteria established for this paper.Results: The results obtained indicated that using siRNA transported via nanosystems was capable of silencing the BRAF tumor genes and of reducing tumor size and weight, not presenting in vitro and/or in vivo toxicity.Conclusion: Such being the case, the development of these systems becomes a non-invasive and promising option for the treatment of melanoma.\",\"PeriodicalId\":10842,\"journal\":{\"name\":\"Current drug delivery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2023-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current drug delivery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/1567201820666230425234700\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1567201820666230425234700","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

背景:黑色素瘤是一种恶性皮肤癌类型，因转移活跃而致死率高。其发展的危险因素之一是暴露于紫外线辐射(UV)和表型特征，如干净的皮肤和眼睛。鉴于常规治疗的困难，治疗的高成本和药物的低生物利用度，开发新的治疗方法来克服这种情况是很重要的。与传统治疗方法相比，胶束、脂质体和纳米颗粒等纳米系统具有优势。目的:本文的目的是对有关sirna负载纳米系统用于黑色素瘤治疗的文章进行文献综述，并进行体内试验以评估肿瘤大小。方法:检索Web of Science和PubMed数据库，检索时间为近5年，即2017年1月至2021年12月。在两个数据库中均使用“SiRNA和药物传递系统及黑色素瘤”关键词，并使用为本文建立的纳入和排除标准对文章进行分析。结果:结果表明，通过纳米系统运输的siRNA能够沉默BRAF肿瘤基因，减小肿瘤的大小和重量，而不表现出体外和/或体内毒性。结论:在这种情况下，这些系统的发展成为治疗黑色素瘤的非侵入性和有希望的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Nanocarriers for Sirna Delivery Aimed at the Treatment of Melanoma: Systematic Review.

Background: Melanoma is a malignant skin cancer type with a high lethality rate due to active metastasis. Among the risk factors for its development is exposure to ultraviolet radiation (UV) and phenotypical characteristics such as clear skin and eyes. Given the difficulties of the conventional therapy, the high cost of the treatment and the low bioavailability of drugs, it is important to develop new therapeutic methods to circumvent this situation. Nanosystems such as micelles, liposomes and nanoparticles present advantages when compared to conventional treatments.

Objective: The objective of this paper is to carry out a literature review based on articles that dealt with the use of siRNA-loaded nanosystems for the treatment of melanoma, with trials carried out in vivo to assess tumor size.

Methods: The search was conducted in the Web of Science and PubMed databases considering the last 5 years, that is, the period between January 2017 to December 2021. The "SiRNA and Drug Delivery Systems and Melanoma" keywords were used in both databases, and the articles were analyzed using the inclusion and exclusion criteria established for this paper.

Results: The results obtained indicated that using siRNA transported via nanosystems was capable of silencing the BRAF tumor genes and of reducing tumor size and weight, not presenting in vitro and/or in vivo toxicity.

Conclusion: Such being the case, the development of these systems becomes a non-invasive and promising option for the treatment of melanoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current drug delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.10

自引率

4.20%

发文量

170

期刊介绍： Current Drug Delivery aims to publish peer-reviewed articles, research articles, short and in-depth reviews, and drug clinical trials studies in the rapidly developing field of drug delivery. Modern drug research aims to build delivery properties of a drug at the design phase, however in many cases this idea cannot be met and the development of delivery systems becomes as important as the development of the drugs themselves. The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance. The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.